They also observed an increase of CD8+ expressing granzyme B, EOMES (Eomesodermin), and TBET (T-box expressed in T cells) in responder patients at early stages of treatment, indicating that effector T cells are needed for an optimal anti-tumor immune response. This evidence concerns the gene CD8A and neoplasm.